Stockholm, Sweden, 13 February 2013 - Sobi (STO: Sobi) announced that it has entered into a distribution agreement with PharmaSwiss to market the products Megace®, Monopril®, Cefzil® and Duricef® approved for the treatment of indications within the oncology, cardio-vascular and anti-infective therapy areas. Under the terms of the agreement, Sobi will have distribution rights in Ireland, United Kingdom, France, Italy, Germany, Spain, Finland, Sweden, Denmark, Norway, Austria, Belgium, Liechtenstein, Netherlands, Portugal, and Luxembourg. All products are approved within the Sobi territory, where sales in 2012 were approximately SEK 120 million (EUR 14 million). Sobi expects to initiate distribution for the portfolio by the end of the first quarter 2013.
Anders Edvell, Vice President and Head of Partner Products at Sobi, said: "We have built a unique European platform with Partner Products to support the complex clinical and reimbursement requirements of niche and specialty products. We are delighted to be able to provide patients and physicians with this portfolio of important treatment options, and to welcome PharmaSwiss as a new partner."
About Megace® (megestrol): Megace is a progestogen hormone drug is indicated for the treatment of certain hormone-dependent neoplasms such as breast cancer.
About Monopril® (fosinopril): Monopril is an angiotensin converting enzyme (ACE) inhibitor indicated for treatment of hypertension and congestive heart failure.
About Cefzil® (cefprozil): Cefzil is a broad-spectrum cephalosporin antibiotic indicated for the treatment of mild to moderate infections.
About Duricef® (cefadroxil): Duricef is a cephalosporin antibiotic indicated for the treatment of urinary tract infections, skin infections, pharyngitis and/or tonsillitis, where the infections are caused by susceptible strains of designated microorganisms.
About Sobi Partner Products
Sobi Partner Products (SPP) is a business unit within Sobi which offers a unique commercial platform for partners with niche and specialty products. SPP provides extensive knowledge and local experience through our direct presence across EU, Eastern Europe, Russia, Middle East and North Africa. We apply an integrated commercial, medical, and market access approach to products which address important unmet needs, working from named patient use (NPU) programs through to reimbursement and commercialization, primarily in the Centre of Expertise setting. The key SPP therapeutic areas are Oncology, Hematology, Infectious Diseases, and Emergency Medicines & Antidotes.
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within hemophilia and neonatology. We also market more than 40 specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2011, Sobi had total revenues of SEK 1.9 billion (€ 214 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
Contact at Sobi
Anders Edvell - Vice President and Head of Partner Products
Phone: +46 8 697 2000
Jorgen Winroth - Vice President Investor Relations
Phone: +46 8 6973427
The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on February 13, 2013 at 08:30 a.m. CET.